7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013)


WELBA Late Breaker Track A
  Oral Abstract Session :
Venue: Session Room 4
Time: 03.07.2013, 16:30 - 17:30
Co-Chairs: Daniel Douek, United States
Sarah Palmer, Australia

16:30
WELBA01
Abstract
Sustained high levels of circulating galectin-9 despite viral suppression among HIV-infected elite controllers
R. Tandon1, T. Fujita1, G. Chew1, J. Barbour1, T. Niki2, M. Hirashima2, J. Martin3, S. Deeks3, L. Ndhlovu1
1University of Hawaii, Hawaii Center for AIDS, Department of Tropical Medicine, Honolulu, United States, 2Kagawa University, Kagawa, Japan, 3University of California San Francisco, HIV/AIDS Division, San Francisco General Hospital, San Francisco, United States

16:40
WELBA02
Abstract
Powerpoint
Naive CD4 T lymphocytes and recent thymic emigrants, 15 or more years after perinatal HIV infection: the ANRS-EP38-IMMIP study
S. Blanche1,2, D. Scott-Algara3, J. Le Chenadec4, C. Didier3, T. Montange3, V. Avettand-Fenoel2,5, C. Rouzioux2,5, J.-P. Viard2,6, C. Dollfus7, N. Bouallag4, J. Warszawski4,8, F. Buseyne3
1AP-HP, Unité Immunologie et Hématologie Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France, 2Université Paris Descartes, Faculté de Médecine, EA3620, Paris, France, 3Institut Pasteur, Virology, Paris, France, 4CESP INSERM U1018, Le Kremlin-Bicêtre, France, 5AP-HP, Laboratoire de Virologie, Hôpital Necker-Enfants Malades, Paris, France, 6AP-HP, Centre de Diagnostic et de Thérapeutique, Hôpital de l'Hôtel-Dieu, Paris, France, 7AP-HP, Service d'Hématologie et d'Oncologie Pédiatrique, Hôpital Trousseau, Paris, France, 8Université Paris-Sud, Le Kremlin-Bicêtre, France

16:50
WELBA03
Abstract
Powerpoint
Gag-positive reservoir cells are identified by a new technique and are susceptible to HIV-specific cytotoxic T lymphocyte
E. Graf1, M. Pace1, L. Lynch1, S. Deeks2, S. Migueles3, U. O'Doherty1
1University of Pennsylvania, Pathology and Laboratory Medicine, Philadelphia, United States, 2UCSF, San Francisco, United States, 3National Institutes of Health, Laboratory of Immunoregulation, NIAID, Bethesda, United States

17:00
WELBA04
Abstract
Powerpoint
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial
J.P. Williams1,2,3, J. Hurst1,2,3, N. Robinson1,2,3, S. Fidler4, J. Weber4, A. Babiker5, R. Phillips1,2,3, K. Koelsch6, T. Kelleher6, J. Frater1,2,3, SPARTAC Trial Investigators
1University of Oxford, Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, Oxford, United Kingdom, 2Oxford National Institute of Health Research Biomedical Research Centre, Oxford, United Kingdom, 3Institute for Emerging Infections, The Oxford Martin School, Oxford, United Kingdom, 4Imperial College London, Division of Medicine, Wright Fleming Institute, London, United Kingdom, 5Medical Research Council Clinical Trials Unit, London, United Kingdom, 6University of New South Wales, Kirby Institute, Sydney, Australia

17:10
WELBA05
Abstract
In depth investigation of peripheral and gut HIV-1 reservoirs, HIV-specific cellular immunity, and host microchimerism following allogeneic hematopoetic stem cell transplantation
T. Henrich1,2, E. Hanhauser1, M. Sirignano3, B. Davis2,3, T.-H. Lee4,5, S. Keating4,5, M. Busch4,5, F. Marty1,2,6, A. LaCasce2,6, P. Armand2,6, R. Soiffer2,6, M. Altfeld2,3,7, D. Kuritzkes1,2
1Brigham and Women's Hospital, Boston, United States, 2Harvard Medical School, Boston, United States, 3Massachusetts General Hospital, Boston, United States, 4Blood Systems Research Institute, San Francisco, United States, 5University of California, San Francisco, San Francisco, United States, 6Dana-Farber Cancer Institute, Boston, United States, 7Ragon Institute of MGH, Harvard & MIT, Cambridge, United States

17:20
WELBA06
Moderated discussion

Powerpoints presentations
Naive CD4 T lymphocytes and recent thymic emigrants, 15 or more years after perinatal HIV infection: the ANRS-EP38-IMMIP study - Florence Buseyne

Gag-positive reservoir cells are identified by a new technique and are susceptible to HIV-specific cytotoxic T lymphocyte - Una O'Doherty

HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial - James Philip Williams



Rapporteur report

Track A report by Uriel Moreno-Nieves


Late Breaker Track A


In this session recent and outstanding data was presented.

L. Ndhlovu showed that Galectin 9 (Gal-9) levels are elevated in elite controllers, a state associated with high levels of HIV-specific T cells and T cell activation. Also that, effective ART is associated with reduction of Gal-9, but the levels remain elevated. And he showed that Tim-3 expression on CD8+ T cells is also elevated in elite controllers reflecting an active Tim-3/Gal-9 axis perhaps leading to the loss of protective CD8 T cells.

J. Williams presented data regarding the SPARTAC trial, which is the largest randomized clinical trial investigating the effect of short-course ART compared to no ART in primary HIV infection (PHI). He showed that 12 or 48 weeks of ART significantly decreases the cell-associated HIV-DNA. Also that viral load at ‘baseline’ associates with HIV-DNA levels at baseline and after therapy. Also, no evidence was found to suggest that proviral load is associated with time to viral rebound. And finally he showed that total and integrated proviral levels predict primary endpoint of the clinical trial.

T. Henrich presented interesting data about 2 patients called the « Bostonian patients ». These 2 HIV-infected patients received reduced-intensity conditioning allogenic hematopoetic stem cell transplantation (RIC-alloHSCT) from WT CCR5 donors while continuing ART. Henrich analyzed the long-term impact of RIC-alloHSCT on viral reservoirs, up to 4.3 years. No HIV-1 DNA was detected from PBMC, no HIV-1 p24 was detected by viral co-culture from purified CD4+ T cells, no HIV-1 DNA was detected in rectal tissue from 1 patient, no HIV-1 specific immune response was observed. Host cells constituted less than 0.001% of PBMC post-HSCT. After analytical treatment interruption, no detectable HIV-1 plasma RNA or PBMC DNA has been found (patient A, after 8 weeks off ART; patient B, after 15 weeks off ARV). These results provide further evidence that donor cells in various tissues are protected from infection by ongoing ART.

The ANRS-EP38 study was presented, which studies children born to HIV infected mothers before 1993 who reached adolescence (approx. 60% of children, with an age of 15-24 years old, most on HAART and 75% aviremic). Naïve T cells and Thymic acitivity were in range of normal. They observed paradoxical associations which suggest enhanced thymopoiesis which is compensated for rates of HIV driven T cell depletion.





   

    The organizers reserve the right to amend the programme.